Fund+
VC Fund
Leuven, Belgium
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Fund+ invests in
Stages Fund+ invests in
Countries Fund+ invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $12M–$47M
- Series B
- $22M–$125M
- Series C
- $11M–$401M
Investment Focus
Industry
- Biotechnology 16 (46%)
- Health Care 12 (34%)
- Therapeutics 9 (26%)
- Medical 8 (23%)
- Pharmaceutical 6 (17%)
Stage
- Series A 10 (29%)
- Series B 10 (29%)
- Series C 3 (9%)
- Venture - Series Unknown 2 (6%)
- Seed 1 (3%)
Country
- Belgium 9 (26%)
- United States 3 (9%)
- Spain 2 (6%)
- France 2 (6%)
- Germany 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Desire Collen
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email | |
Philippe Monteyne
Partner
|
Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $11.9M / Convertible Note / Sep 21, 2026 | ||
| Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $86.6M / Series B / Jun 04, 2026 | ||
| TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M / Series A / Dec 16, 2025 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M / Series C / Oct 15, 2025 | ||
| Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. | $11.6M / Venture - Series Unknown / Oct 09, 2025 | ||
| Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $32.9M / Series A / Jan 09, 2025 | ||
| Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M / Series B / Jul 26, 2024 | ||
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $139.3M / Series B / Mar 14, 2024 | ||
| Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M / Series B / Nov 03, 2022 | ||
| AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. | $29.9M / Seed / Aug 25, 2022 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fund+ invest in?
Fund+ invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Fund+ invest in?
Fund+ typically joins rounds of $12M–$47M at Series A, $22M–$125M at Series B and $11M–$401M at Series C. These are whole funding-round sizes, not Fund+'s own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Fund+ took part in.
How do I contact Fund+?
Public channels for Fund+ include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fund+?
The team at Fund+ includes Desire Collen (Founder & Chairman) and Philippe Monteyne (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
